A Phase 4 interventional study of Quizartinib and Chemotherapy in Acute Myeloid Leukemia, sponsored by Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company (part of Daiichi Sankyo) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Leukemia, Myeloid, Acute by Daiichi Sankyo — 2 open to participants now, 4 under way, 1 of them phase 3. Leukemia, Myeloid, Acute · Daiichi Sankyo.
Among the 22 studies in Leukemia, Myeloid, Acute by Daiichi Sankyo, this one is the 12th largest by planned enrollment of the 21 interventional ones that give a count, is the only one that started in 2026, is the only one in phase 4, and was the 22nd registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 813 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →2 of the 22 studies in Leukemia, Myeloid, Acute by Daiichi Sankyo are open now, in 5 countries. Recruiting first, the newest first:
Daiichi Sankyo · Sites in United States, Australia, Brazil and 2 more countries
Ages 18+
By country, each count listing its studies:
Of the 621 Leukemia, Myeloid, Acute studies recruiting now, 361 (58%) set no upper age limit and 220 (35%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 6 · Phase 3 3 · Phase 4 1
First in 1999; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is close to the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 50 across the 21 interventional studies. Of the 18 that completed or were terminated, 12 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company, one of the names counted as Daiichi Sankyo. Under that name alone:
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company is the lead sponsor of 19 studies on the registry; 3 are open to participants now.
1 of the studies in Leukemia, Myeloid, Acute by Daiichi Sankyo that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03793478Daiichi SankyoSafety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood | 2027-05-01 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies in Leukemia, Myeloid, Acute by Daiichi Sankyo, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The clinical trial is designed to assess the safety of quizartinib in newly diagnosed FLT3-ITD (+) AML in Chinese participants.
This is a Phase 4, open-label, single-arm, interventional trial evaluating the safety and efficacy of quizartinib administered in combination with induction and consolidation chemotherapy and administered as maintenance monotherapy in Chinese adult participants with newly diagnosed FLT3-ITD (+) AML. Eligible participants will be administered quizartinib in combination with chemotherapy in the Induction and Consolidation Phases and administered with quizartinib monotherapy in the Maintenance Phase. The trial will be divided into 3 periods: screening period, treatment period (Induction Phase, Consolidation Phase, and Maintenance Phase), and long-term follow-up (LTFU) period.
Key Inclusion Criteria:
To be eligible to participate in this trial, an individual must meet all the following criteria:
Key Exclusion Criteria:
Individual who meets any of the following criteria will be excluded from participation in this trial:
Prior treatment for AML, except for the following allowances:
Note: Other protocol pre-specified inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive up to 2 cycles of induction chemotherapy along with quizartinib 40 mg orally once daily for 14 days starting at Day 8 of Cycle 1, followed by up to 4 cycles of consolidation chemotherapy along with quizartinib 40 mg orally once daily for 14 days starting Day 6, with optional allogeneic hematopoietic stem cell transplantation \[HSCT\]), followed by up to 36 cycles of maintenance monotherapy with quizartinib 30 mg orally once daily, on Cycle 1 Day 1 increased to 60 mg once daily on Cycle 1 Day 16.
Drug: Quizartinib · Drug: Chemotherapy · Genetic: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Participants will receive quizartinib 40 mg orally once daily for 14 days during the induction and consolidation phases and 30 mg orally once daily, increased to 60 mg once daily in the maintenance phase.
Participants will receive commercially available cytarabine (cytosine arabinoside) and anthracycline (daunorubicin or idarubicin).
Also known as: Daunorubicin, Idarubicin, Standard Chemotherapy, Cytarabine
Allogeneic HSCT is one of the options for consolidation therapy.
Percentage of Participants With Grade Greater than or Equal to (≥)3 Treatment-Related Adverse Events (TRAEs)
An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TRAEs are defined as those AEs considered to be related to quizartinib by the investigators with start or worsening date during the on-treatment period (from the first dose date of quizartinib to 30 days after the last dose date of quizartinib).
Time frame: Up to approximately 39 months
Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)
Other safety parameters may also be assessed. These include serious TEAEs, adverse events of special interests (AESIs), changes in vital signs, electrocardiogram (ECG) findings, safety laboratory assessments and physical examinations.
Time frame: Up to approximately 39 months
Composite Complete Remission (CRc) Rate
CRc rate is defined as the percentage of participants who achieved composite complete remission (CRc), where CRc is defined as complete remission (CR) + complete remission with incomplete neutrophil or platelet recovery (CRi) after induction.
Time frame: At the end of induction, up to 2 cycles (each cycle=28 days)
Complete Remission (CR) Rate
CR rate is defined as percentage of participants who achieved a CR after induction.
Time frame: At the end of induction, up to 2 cycles (each cycle=28 days)
Event-Free Survival (EFS)
EFS is defined as time from enrollment until the date of the earliest of any of the following: refractory disease (or treatment failure) which is determined at the end of the induction phase; relapse after CR or CRi; death from any cause since enrollment.
Time frame: Up to approximately 39 months
Relapse-Free Survival (RFS)
RFS is defined as the time from enrollment, for participants who achieve CR or CRi in the induction phase, until documented relapse or death from any cause, whichever comes first.
Time frame: Up to approximately 39 months
Overall Survival (OS)
OS is defined as the time from enrollment until death from any cause.
Time frame: Up to approximately 39 months
Plasma Concentration of Quizartinib and AC886
Time frame: Up to approximately 39 months
No study locations are listed for this record.
Plan to share: Yes — De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Completed studies that has reached a global end or completion with all data set collected and analyzed, and for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Jun 2030, 42 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company →